Cargando…

LB1528C. Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial

BACKGROUND: The effectiveness of ivermectin to shorten symptom duration or prevent hospitalization among outpatients in the United States with mild-to-moderate symptomatic coronavirus disease 2019 (COVID-19) is unknown. We evaluated the efficacy of ivermectin 400 µg/kg daily for 3 days compared with...

Descripción completa

Detalles Bibliográficos
Autor principal:	Naggie, Susanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752828/ http://dx.doi.org/10.1093/ofid/ofac492.1883

Ejemplares similares

LB1528. Results from ACTIV-6: A Decentralized, Double-Blinded, Randomized, Placebo-Controlled Platform Trial of Repurposed Drugs for the Treatment of Mild-to-Moderate COVID-19
por: McCarthy, Matthew W
Publicado: (2022)

1528. Rates of Peripheral Blood Culture Contamination in an Urban Children’s Hospital
por: Tam, Derek, et al.
Publicado: (2019)

1528. A Real-World Perspective on Treatment of CRE UTIs With Oral Agents
por: Babiker, Ahmed, et al.
Publicado: (2018)

Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial
por: Manomaipiboon, Anan, et al.
Publicado: (2022)

Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY)
por: Horga, Arantxa, et al.
Publicado: (2023)

Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial
por: Mohan, Anant, et al.
Publicado: (2021)

Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial
por: Wada, Tatsuhiko, et al.
Publicado: (2023)

126. Outpatient Antimicrobial Stewardship Utilizing a Decentralized Model
por: Powers, Harry, et al.
Publicado: (2021)

Erratum: Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial
Publicado: (2023)

1528 Ralteragir Containing regimen, for Post Exposure Prophylaxis (PEP), well tolerated in Health Care Workers (HCW)
por: Bourgi, Kassem, et al.
Publicado: (2014)

1528. Prevalence of Human Papillomavirus Infection and Cervical Intra-Epithelial Lesions in A Subset of Arab American Women in Southeast Michigan
por: Shallal, Anita, et al.
Publicado: (2020)

1528. Retrospective cohort study of factors associated with non-initiation of antiretroviral therapy among adults newly diagnosed with HIV in Andijan, Uzbekistan, 2018-2021
por: Usmanov, Shokhruh, et al.
Publicado: (2023)

1349. Unveiling the Link between COVID-19 and the Gut Microbiome in an Outpatient Cohort with Mild to Moderate Illness
por: Comba, Isin Y, et al.
Publicado: (2023)

Spanish explorers in the Southern United States, 1528- 1543 : the Narrative of Alvar Nuñez Cabeza de Vaca /
Publicado: (1925)

ACTIV-6: Operationalizing a decentralized, outpatient randomized platform trial to evaluate efficacy of repurposed medicines for COVID-19
Publicado: (2023)

Ivermectin compared with placebo in the clinical course in Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial
por: de la Rocha, Carmen, et al.
Publicado: (2022)

Non-effectiveness of Ivermectin on Inpatients and Outpatients With COVID-19; Results of Two Randomized, Double-Blinded, Placebo-Controlled Clinical Trials
por: Rezai, Mohammad Sadegh, et al.
Publicado: (2022)

521. A phase II, double blind, placebo-controlled, randomized evaluation of the safety and efficacy of tafenoquine in patients with mild-moderate COVID-19 disease
por: Dow, Geoffrey
Publicado: (2023)

LB17. Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
por: Hughes, Brenna
Publicado: (2019)

Platform Architecture for Decentralized Positioning Systems
por: Kasmi, Zakaria, et al.
Publicado: (2017)

A randomized, controlled, feasibility study of RD‐X19 in subjects with mild‐to‐moderate COVID‐19 in the outpatient setting
por: Stasko, Nathan, et al.
Publicado: (2022)

LB10. A Randomized, Double-Blind, Placebo-Controlled Efficacy Trial of a Vaccine to Prevent Chronic Hepatitis C Virus Infection in an at-Risk Population
por: Cox, Andrea L, et al.
Publicado: (2019)

La Catedral de San Cristóbal de Las Casas, Chiapas, 1528-1978 /
por: Flores Ruiz, Eduardo, 1890-1977
Publicado: (1978)

Increased risk of psychosis to ivermectin treatment
por: Romero Calderon, A., et al.
Publicado: (2022)

PO-1528 Mood disorder in cancer patients undergoing radiotherapy during the COVID-19 outbreak
por: Nardone, V., et al.
Publicado: (2021)

301. Risk of Virologic Failure with Antiretroviral Switches in HIV/HCV Co-infections
por: Mosquera, Diana M, et al.
Publicado: (2019)

Oral nano‐curcumin formulation efficacy in the management of mild to moderate outpatient COVID‐19: A randomized triple‐blind placebo‐controlled clinical trial
por: Ahmadi, Reza, et al.
Publicado: (2021)

2549. Variance Between Clinicians and Guidelines in Management of HIV/HCV Coinfection
por: Naggie, Susanna, et al.
Publicado: (2019)

La historia de Texas en la Biblioteca Nacional de México, 1528-1848 : bibliografía comentada /
por: Curiel, Guadalupe
Publicado: (1994)

LB1. Remdesivir for the Treatment of High-Risk Non-Hospitalized Individuals With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Hill, Joshua A, et al.
Publicado: (2021)

Effects of Oxygen Transference on Protease Production by Rhodotorula mucilaginosa CBMAI 1528 in a Stirred Tank Bioreactor
por: Machado, Suellen, et al.
Publicado: (2022)

The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial
por: Hosseini, Fatemeh Sadat, et al.
Publicado: (2021)

Neuroanatomical Moderators of the Impact of Mild Behavioral Impairment on Cognition
por: Rouse, Hillary, et al.
Publicado: (2021)

1465. Discovering Outpatient Stewardship Targets: An Evaluation of Community Acquired Pneumonia in the Outpatient Setting
por: Wattengel, Bethany, et al.
Publicado: (2018)

1842. Fluoroquinolone Usage Reduction in the Outpatient Setting
por: Mang, Norman, et al.
Publicado: (2018)

2077. Fluoroquinolone Usage Reduction in the Outpatient Setting
por: Lin, Kevin, et al.
Publicado: (2019)

New Therapeutic Options in Mild Moderate COVID-19 Outpatients
por: Ucciferri, Claudio, et al.
Publicado: (2022)

DeTi: A Decentralized Ticketing Management Platform
por: Rafati Niya, Sina, et al.
Publicado: (2022)

The effect of ivermectin on the viral load and culture viability in early treatment of nonhospitalized patients with mild COVID-19 – a double-blind, randomized placebo-controlled trial
por: Biber, Asaf, et al.
Publicado: (2022)

P1528: GENETIC AND PHENOTYPIC CHARACTERIZATION OF HEREDITARY SPHEROCYTOSIS AND RELATED DISORDERS – DESCRIPTION OF 9 NEW GENETIC VARIANTS
por: Haeuser, F., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4rquarii2ab75hmbgsaqtlkpk3